A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

Summary

This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.

Conditions

• Breast Carcinoma
• Colorectal Carcinoma
• Lung Carcinoma
• Malignant Solid Neoplasm
• Prostate Carcinoma

Interventions

OTHER

Educational Intervention

Receive educational materials and resources

OTHER

Electronic Health Record Review

Ancillary studies

PROCEDURE

Follow-Up

Receive follow-up contact

OTHER

Internet-Based Intervention

Use self-monitoring platform

OTHER

Interview

Ancillary studies

OTHER

Survey Administration

Ancillary studies

Sponsors & Collaborators

• Agency for Healthcare Research and Quality (AHRQ)

  collaborator FED

• University of Michigan Rogel Cancer Center

  lead OTHER

Principal Investigators

• Yun Jiang · University of Michigan Rogel Cancer Center

• Yang Gong · UTHealth Houston McWilliam School of Biomedical Informatics

Study Design

Allocation

NA

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-01-09

Primary Completion

2028-01-01

Completion

2028-01-01

Countries

• United States

Study Locations